NYSE - Nasdaq Real Time Price USD

Quest Diagnostics Incorporated (DGX)

175.87

+2.30

+(1.33%)

At close: April 24 at 4:00:02 PM EDT

175.57

-0.30

(-0.17%)

Pre-Market: 4:40:06 AM EDT

Quest Diagnostics First Quarter 2025 Earnings: EPS Beats Expectations

Quest Diagnostics ( NYSE:DGX ) First Quarter 2025 Results Key Financial Results Revenue: US$2.65b (up 12% from 1Q...

Simply Wall St. yesterday

DGX
+1.33%
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Quest Diagnostics Inc (DGX) reports a robust 12% revenue increase and reaffirms its positive financial outlook for 2025, driven by strategic advancements and partnerships.

GuruFocus.com 2 days ago

DGX
+1.33%
Q1 2025 Quest Diagnostics Inc Earnings Call

Q1 2025 Quest Diagnostics Inc Earnings Call

Thomson Reuters StreetEvents 2 days ago

DGX
+1.33%
'Safe Haven' Stock Quest Diagnostics Bounds Off 50-Day Line On Its Solid Report

Quest Diagnostics stock remains a "safe haven," an analyst said Tuesday after the company topped first-quarter expectations.

Investor's Business Daily 2 days ago

DGX
+1.33%
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up

DGX delivers solid top-line growth in the first quarter of 2025.

Zacks 2 days ago

DGX
+1.33%
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 2.79% and 1.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 days ago

DGX
+1.33%
Quest beats quarterly profit estimates on strong demand for diagnostic tests

Demand for diagnostic checkups has grown in recent quarters as more people, especially older Americans, have sought non-urgent surgeries they had delayed. Diagnostic service providers such as Quest and Labcorp have also benefited from deals to manage hospital labs as they seek market share gains. "We were not expecting any real fireworks here but rather a continuation of a slow and steady performance, and at first glance that is what 1Q delivered," Leerink Partners analyst Michael Cherny said in a note.

Reuters 2 days ago

DGX
+1.33%
Quest (NYSE:DGX) Beats Q1 Sales Targets

Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.65 billion. The company expects the full year’s revenue to be around $10.78 billion, close to analysts’ estimates. Its non-GAAP profit of $2.21 per share was 2.8% above analysts’ consensus estimates.

StockStory 2 days ago

DGX
+1.33%
Quest Diagnostics: Q1 Earnings Snapshot

SECAUCUS, N.J. (AP) — Quest Diagnostics Inc. DGX) on Tuesday reported first-quarter earnings of $220 million. On a per-share basis, the Secaucus, New Jersey-based company said it had profit of $1.94.

Associated Press Finance 2 days ago

DGX
+1.33%
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.

PR Newswire 2 days ago

DGX
+1.33%
Quest Diagnostics Incorporated (DGX): A Bull Case Theory

We came across a bullish thesis on Quest Diagnostics Incorporated (DGX) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on DGX. Quest Diagnostics Incorporated (DGX)’s share was trading at $163.80 as of April 17th. DGX’s trailing and forward P/E were 21.30 and 16.86 respectively according to Yahoo Finance. Despite signs that […]

Insider Monkey 3 days ago

DGX
+1.33%
Quest Earnings: What To Look For From DGX

Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) will be reporting earnings tomorrow before market hours. Here’s what you need to know.

StockStory 3 days ago

DGX
+1.33%
3 Healthcare Stocks with Questionable Fundamentals

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 15.5%. This drop was worse than the S&P 500’s 10% fall.

StockStory 6 days ago

LFST

GDRX

DGX
+1.33%
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 8 days ago

AMED

DGX
+1.33%
Quest Diagnostics price target raised to $198 from $190 at BofA

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially aro

TipRanks 9 days ago

DGX
+1.33%
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 9 days ago

DGX
+1.33%
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings

DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.

Zacks 9 days ago

DGX
+1.33%
DGX Stock Gains Following the Launch of New AD-Detect Blood Test

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.

Zacks 13 days ago

DGX
+1.33%
BSX

CAH
+1.05%
Quest introduces blood test to confirm amyloid brain pathology in Alzheimer’s

The test is currently available to physicians across the US, excluding New York.

Medical Device Network 14 days ago

DGX
+1.33%
Quest Diagnostics (NYSE:DGX) Unveils New Alzheimer's Blood Test With Promising Predictive Accuracy

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the company's stock price moved up by 4%, despite broader market declines of 12% driven by tariff-related uncertainties. Quest's robust performance, alongside its collaboration with GRAIL and a 6.7% dividend increase, provided a counterbalance to the volatile market conditions. While the healthcare sector...

Simply Wall St. 15 days ago

DGX
+1.33%

Performance Overview

Return	DGX	S&P 500 (^GSPC)
YTD	+17.72%	-6.75%
1-Year	+30.45%	+8.15%
3-Year	+36.35%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Quest Diagnostics Incorporated (DGX)

Quest Diagnostics First Quarter 2025 Earnings: EPS Beats Expectations

Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Q1 2025 Quest Diagnostics Inc Earnings Call

'Safe Haven' Stock Quest Diagnostics Bounds Off 50-Day Line On Its Solid Report

Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up

Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates

Quest beats quarterly profit estimates on strong demand for diagnostic tests

Quest (NYSE:DGX) Beats Q1 Sales Targets

Quest Diagnostics: Q1 Earnings Snapshot

Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

Quest Diagnostics Incorporated (DGX): A Bull Case Theory

Quest Earnings: What To Look For From DGX

3 Healthcare Stocks with Questionable Fundamentals

Amedisys (AMED) Earnings Expected to Grow: Should You Buy?

Quest Diagnostics price target raised to $198 from $190 at BofA

Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?

Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings

DGX Stock Gains Following the Launch of New AD-Detect Blood Test

Quest introduces blood test to confirm amyloid brain pathology in Alzheimer’s

Quest Diagnostics (NYSE:DGX) Unveils New Alzheimer's Blood Test With Promising Predictive Accuracy

Performance Overview